Healthcare Sector
Sector Expertise
Apax Partners is one of the leading global investors in the Healthcare sector, having completed more than 100 healthcare transactions since inception. Over the past five years, Apax has invested over €2.5 billion in Healthcare across multiple geographies including the US, Europe and Asia.
Apax has deep sector expertise in the key Healthcare sub-categories, including Services, Pharmaceuticals, IT and Devices & Products. Recent deals include: Marken (Services); Qualitest (Pharma); TriZetto (IT) and Mölnlycke (Products).
Led by Buddy Gumina and Khawar Mann, the Apax Healthcare team has strong global presence, with investment professionals in multiple countries around the world. The team has a range of complimentary backgrounds, including operations, academic research, banking and consulting, which it utilizes to identify outstanding investment opportunities and to be effective, value-added partners for portfolio company management teams.
News
Apax Partners sells Spectrum Holding Company, Inc. for $230 million
Funds advised by Apax Partners today announced the sale of Spectrum Holding Company, Inc. to Welsh, Carson, Anderson & Stowe for $230 million.
Apax Partners’ Funds acquire Healthcare leader Marken
A consortium comprising funds advised by Apax Partners and company management has reached agreement to acquire Marken, a company specialising in clinical trial logistics, for an undisclosed sum from Intermediate Capital Group.
Apax Partners completes acquisition of TriZetto Group
The TriZetto Group, Inc. and Apax Partners announced today the closing of the merger pursuant to which funds advised by Apax Partners, together with minority investors BlueCross BlueShield of Tennessee and The Regence Group, acquired all of TriZetto’s common stock for $22 cash per share.
Sector Insight
 |
Mölnlycke Health Care Group
The consolidation of three European companies to build a world leader in the medical products space
Read More >> |
Specialty pharmaceuticals
The success or failure of large pharmaceutical companies is driven by the so-called blockbuster drugs that have annual sales of at least $1 billion and are used by tens of millions of patients.
However, blockbusters aren't everything.
Read More >>